| August 2008: |
DiagnoCure launches its Previstage™ GCC Colorectal Cancer Staging Test, available through its CLIA-certified clinical laboratory, DiagnoCure Oncology Laboratories. |
| December 2007: |
DiagnoCure initiates the establishment of its U.S.-based clinical laboratory in West Chester, Pennsylvania. |
| August 2007: |
DiagnoCure acquires Catalyst Oncology and its proprietary prognostic tests based on the measure of the Shc proteins for breast, colon and potentially other cancers. |
| April 2007: |
DiagnoCure secures exclusive worldwide rights to two high-value molecular tests based on the detection of GCC for colorectal cancer. |
| April 2007: |
Completion of
a public offering of common shares for gross proceeds of $25,155,000. |
| November 2006: |
Gen-Probe's PCA3 test receives European CE Mark and is launched in six laboratory sites across Europe. |
| October 2006: |
DiagnoCure enters into an agreement with Radboud University Medical Center of Nijmegen, the Netherlands, covering technology rights related to Dr. Jack Schalken's discoveries of the role of specific FOX genes expression in prostate cancer. |
| May 2006: |
DiagnoCure and Gen-Probe expand the terms of their agreement and collaboration for the research of additional applications of the PCA3 gene, and the evaluation of certain lung cancer markers. |
| March 2006: |
DiagnoCure’s exclusive rights to PCA3, its highly prostate-cancer specific gene, are confirmed as the United States Patent and Trademark Office (USPTO) grants a patent on the PCA3 gene technology, which encompasses both therapeutic and diagnostic applications. |
| July 2004: |
Completion of a public offering of common shares for gross proceeds of $23,750,000. |
| December 2003: |
DiagnoCure acquires assets of Samba Technologies, a company specializing in digital imaging and computer technology. |
| November 2003: |
Gen-Probe and DiagnoCure enter into a collaboration agreement for the joint development and commercialization by Gen-Probe of a molecular test for the detection of the PCA3 gene for the diagnosis of prostate cancer. |
| September 2003: |
Conclusion of an agreement with Bostwick Laboratories (US) for the supply of our uPM3™ test for prostate cancer in an ASR format. |
| August 2003: |
Negotiation and conclusion of agreements with Molecular Diagnostics Inc. and Samba Technologies for the automation process of the ImmunoCyt™/uCyt+™ test. |
| March 2003: |
DiagnoCure completed the implementation of its Quality System and is certified ISO 13485-96 (now ISO 13485-2003)– Quality Systems – Medical Devices – Particular Requirements for the application of ISO 9001. |
| September 2002: |
Issue of preliminary results on our uPM3™ test for the detection of prostate cancer. |
| January 2002: |
DiagnoCure and Compugen Ltd. announced an agreement to co-develop molecular diagnostic cancer products. |
| December 2001: |
Completion of a public offering of common shares with gross proceeds of $8.625 million. |
| June 2001: |
Developed the prostate cancer detection test uPM3™. Set up protocols and performed preliminary clinical studies on more than 200 patients. |
| May 2000: |
DiagnoCure acquired from Nijmegen University (The Netherlands) an exclusive worldwide license for all diagnostic and therapeutic applications of the PCA3 gene technology, a specific prostate cancer marker. |
| March 2000: |
Clearance by the FDA to commercialize ImmunoCyt™ in the United States. |
| December 1999: |
Shares listed on the Toronto Stock Exchange on December 6, 1999. |
| October 1999: |
Signed a distribution agreement with DAKO Corporation to handle the commercialization and distribution of ImmunoCyt™ in the United States. |
| During 1998: |
Agreements to distribute ImmunoCyt™ in Europe; agreement with Faulding (Canada) Inc. to jointly commercialize ImmunoCyt™ in the Canadian market. |
| August 1997: |
Obtained a cross-licensing agreement for NASBA molecular amplification technology with Organon Teknika (Belgium), a subsidiary of the Dutch multinational, Akzo Nobel. |
| November 1996: |
Issue of common shares and warrants on the Montreal Stock Exchange in the course of the Company's initial public offering. The net proceeds amounted to $13.4 million (Can.). |
| November 1995: |
Private financing of $6 million (Can.). |
| December 1994: |
Incorporation of the Company. |
